Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07343778 | A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis | PHASE3 | RECRUITING | 300 | — | — | Mar 16, 2026 | Oct 30, 2026 | Mar 31, 2026 | 1 | China |
| Arm | Type | Description |
|---|---|---|
| Hydronitone Capsules group | EXPERIMENTAL | Eligible subjects who passed screening were enrolled sequentially in this study and received Hydronidone Capsules 120mg TID for 28 consecutive days. |
| Name | Type | Description |
|---|---|---|
| Hydronidone Capsules | DRUG | 120mg TID for 28 consecutive days |
Inclusion Criteria: * Participants fully understand the study, voluntarily participate, and have signed the informed consent form (ICF). * Aged ≥18 years, regardless of gender. * Have a confirmed diagnosis of hepatic fibrosis or cirrhosis based on either: A prior percutaneous liver biopsy (results...